Article
Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
Antiviral chemistry & chemotherapy - 1 Jan 2001
Liaw Y F
Abstract excerpt
Lamivudine is a nucleoside analogue with potent inhibitory effects on hepatitis B virus (HBV) replication. Prolonged therapy is required for sustained suppression. However, HBV species with mutations in the tyrosine-methionine-aspartate-aspartate (YMDD) locus of the HBV RNA-dependent DNA polymerase conferring resistance to lamivudine may emerge after 9-10 months therapy with an incidence of 38 and 67% after 2 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
